Investigational drug · Phase 2
NGM120
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Colorectal Cancer, CRC (Colorectal Cancer), Cancer Cachexia.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "NGM120"
First trial start
2025
Jun 25, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NGM120", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colorectal Cancer
- CRC (Colorectal Cancer)
- Cancer Cachexia
Approved drugs for the same conditions: Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "NGM120" as an intervention, largest first.
- An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.Pivotal-lookingRecruiting
NGM Biopharmaceuticals, IncIndustry
NCT07033026 · 136 participants (planned) · Start Jun 25, 2025 · Primary completion Apr 2027
Drug: NGM120 Q4W; NGM120 Q8W and 1 more · For: Colorectal Cancer; CRC (Colorectal Cancer); Cancer Cachexia
Sites: Los Angeles, California; Santa Rosa, California; Margate, Florida · 28 sites in all
NGM Biopharmaceuticals, IncIndustry
NCT03392116 · 92 participants · Start Jan 29, 2018 · Primary completion Jan 14, 2019
Drug: NGM120 · For: Cachexia
Sites: Melbourne, Australia
NGM Biopharmaceuticals, IncIndustry
NCT04068896 · 89 participants · Start Oct 16, 2019 · Primary completion Sep 21, 2023
Drug: NGM120 30mg; NGM120 100mg and 3 more · For: Pancreatic Cancer; Metastatic Castration-resistant Prostate Cancer; Bladder Cancer and 8 more
Sites: Tucson, Arizona; Los Angeles, California; Sacramento, California · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Decoding GDF15: Impact on prostate cancer metabolism, chemoresistance, and clinical applications.
Zhu W, Xu H, Xiong X, et al. · Chin Med J (Engl) 2026
- Advancements of investigational agents for cancer cachexia: what clinical progress have we seen in the last 5ߙyears?
Muscaritoli M, Molfino A, Orlando S, et al. · Expert Opin Investig Drugs 2025
Also in development for Colorectal Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.